Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAA therapy in HCV+ donor to HCV- recipient heart transplant
NCT03208244Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Primary endpoint: Undetectable HCV RNA at 12 Weeks Post Treatment. Started Nov 2017; status: terminated.
02
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03208244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208244.